Boston Scientific Applies Lessons From Taxus Recall To Ireland Plant
This article was originally published in The Gray Sheet
Executive Summary
Stent delivery catheter flaws that provoked a 96,000-unit recall will be prevented by newly installed laser control software at Boston Scientific's Galway, Ireland facility, according to the firm
You may also be interested in...
Boston Scientific Taxus U.S. Market Share Recoups From 56% Low On Recall
Boston Scientific's average Taxus drug-eluting stent sales of $7.4 mil. a day in the U.S. for the week ended Aug. 27 represents a return to 70% market share after dipping to 56% in the wake of a July recall, the firm says
Boston Scientific Taxus U.S. Market Share Recoups From 56% Low On Recall
Boston Scientific's average Taxus drug-eluting stent sales of $7.4 mil. a day in the U.S. for the week ended Aug. 27 represents a return to 70% market share after dipping to 56% in the wake of a July recall, the firm says
CDRH Inspectors To Tour Unlucky Irish Facility After Taxus Recall Expands
FDA will inspect Boston Scientific's Galway, Ireland stent manufacturing facility to ensure the plant's quality control processes are consistent with those implemented at the firm's Maple Grove, Minn. site